Evolus, Inc. commercializes cash-pay medical aesthetic products for the global performance beauty market. Its portfolio centers on Jeuveau® (prabotulinumtoxinA-xvfs), known as Nuceiva® outside the United States, and injectable hyaluronic acid gel collections marketed under the Evolysse® and Estyme® brands.
Recurring Evolus news includes quarterly financial results, revenue outlooks, product and market expansion for injectable aesthetics, CE Mark certification for HA gel collections, national-account and customer engagement updates, healthcare conference participation, and equity compensation grants under Nasdaq inducement rules. Company updates also discuss operations across the United States, Canada, Europe, and Australia.
Evolus (EOLS) entered an option agreement with a privately held company developing an injectable hair restoration treatment, expanding its development pipeline.
Evolus will make an initial $1.5 million option payment, with additional stage-gated payments tied to program milestones, and support development and an initial clinical proof-of-concept study. It has the option, but no obligation, to acquire 100% of the program assets after the initial clinical dataset. Evolus expects formulation development to continue through 2027, with first-in-human clinical development beginning thereafter. The company says the program will not affect its previously communicated revenue or profitability outlook.
Evolus (EOLS) launched Wings by Evolus, a charitable platform bringing aesthetic practices, providers and patients together to support charitable causes.
The first initiative supports Look Good Feel Better during Breast Cancer Awareness Month, running October 1–31, 2026. Evolus will donate $1 for every Evolus Rewards patient check-in at a participating practice. Practices opt in through the Evolus customer portal, at no cost to practices or patients and without changing the check-in experience. Look Good Feel Better provides free programs addressing appearance-related effects of cancer treatment.
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) has appointed David Gill as Chair of its Board, effective immediately, succeeding interim Chair Dr. Mark Nelson, who remains a Non-Executive Director. Gill joined Telix as a Non-Executive Director in May 2026 as part of Board expansion and succession planning.
According to Telix, Gill brings over 35 years of senior leadership experience in commercial and clinical-stage biopharmaceutical, radiopharmaceutical and medical device companies, including prior CFO or President roles at several publicly traded firms. He also currently serves on the boards of Evolus (NASDAQ: EOLS) and other healthcare companies.
Evolus (NASDAQ: EOLS) reported second quarter 2026 net revenue of $84.1 million, up 21% year over year, including $75.2 million from global toxin products and $8.9 million from injectable hyaluronic acid (HA) gels. GAAP loss from operations was $4.5 million, while Adjusted EBITDA was positive $4.7 million, marking a third consecutive quarter of positive Adjusted EBITDA and a $12.6 million improvement over the prior-year period.
Gross margin was 68.0% and adjusted gross margin 69.0%, aided by ~120 basis points from a tariff refund. As of June 30, 2026, cash and cash equivalents were $45.2 million. Evolus raised 2026 net revenue guidance to $330–$337 million, increased adjusted gross margin guidance to 67.0%–67.5%, and narrowed non-GAAP operating expenses to $212–$216 million, while reaffirming a low- to mid-single digit Adjusted EBITDA margin outlook and its 2028 targets of $450–$500 million revenue and 13%–15% Adjusted EBITDA margin.
Strategically, Evolus launched its Estyme HA gel line in Europe, expanded its Symatese licensing deal to Canada, Australia and New Zealand, secured exclusive U.S. rights to develop and commercialize Profhilo, and continued advancing Evolysse Sculpt through FDA review.
Evolus (NASDAQ:EOLS) expanded its strategic partnership with Symatese via an amendment to their licensing and distribution agreement, granting Evolus exclusive rights to commercialize the Estyme injectable hyaluronic acid (HA) gel collection in Canada, Australia, and New Zealand.
Commercialization is expected in 2028, subject to regulatory approvals. With this deal, Evolus will hold exclusive rights to its injectable HA gel portfolio in every market where it currently sells Jeuveau and Nuceiva, creating a consistent multi-product platform. Symatese retains responsibility for development, manufacturing, clinical support, and regulatory activities. Evolus will pay an upfront fee, regulatory milestone payments, product transfer price, and a mid-single digit royalty on net sales. According to Evolus, the agreement should be accretive to international gross margins and leverages existing commercial and digital infrastructure across these markets, which together represent an estimated $500 million annual neurotoxin and dermal filler market.
Evolus (NASDAQ:EOLS) will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after the U.S. markets close. Management will host a conference call and live webcast at 4:30 p.m. ET, followed by a Q&A session and providing replay and archived webcast access.
Evolus (NASDAQ: EOLS) reported that from April 2026 through July 2026 it granted an aggregate of 115,000 restricted stock units (RSUs) to 38 newly hired non-executive employees. The RSUs, issued under the 2023 Inducement Incentive Plan, vest 25% annually starting on grant-specific vesting commencement dates, contingent on continuous employment and made in accordance with Nasdaq Listing Rule 5635(c)(4).
Evolus (NASDAQ:EOLS) entered an exclusive licensing and distribution agreement with Swiss pharma company IBSA to develop and commercialize Profhilo in the United States. Profhilo is a market-leading injectable for skin quality in Europe, sold in 70+ countries with over 4.8 million treatments.
Evolus will handle U.S. regulatory development and commercialization. The deal has no upfront payments, uses a transfer-price model to support gross margins, and is not expected to change 2026 revenue or 2028 profitability targets.
Evolus (NASDAQ:EOLS) announced that its management team will participate in a fireside chat and investor meetings at the Jefferies Global Healthcare Conference in New York City.
The fireside chat is scheduled for Thursday, June 4, 2026, at 12:50 PM ET and will be webcast with a 90-day replay.
Evolus (NASDAQ:EOLS) will commercially launch its Estyme injectable hyaluronic acid gel collection in Europe on May 16, marking entry into the international dermal filler market. The CE‑marked portfolio includes Estyme Smooth, Form, Lips and flagship Sculpt, supported by pivotal studies and Cold-X technology for natural-looking, long-lasting results.